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To improve health management and facilitate cardiovascular disease (CVD) prevention, it is necessary to identify and 
control cardiovascular risk factors appropriately at an early 
stage. Among surrogate markers of cardiovascular risk, vascular 
function, especially aortic stiffness, which can be assessed non-
invasively, is a robust predictor of CVD end points and all-cause 
mortality.1,2 The role of pulmonary function in arterial stiffening 
has been studied less than other risk factors. As many as 1 in 5 
of the general population may have abnormal spirometry pat-
terns3 and impairment of pulmonary function is a risk factor for 
incident angina, myocardial infarction, stroke, and CVD mor-
tality,4–7 making it important to identify the mechanisms under-
lying the association between pulmonary function and CVD. 
Arterial stiffness is among plausible candidates.
Prior observational studies, including 2 prospective stud-
ies,8,9 showed inconsistent associations between pulmonary 
function and arterial stiffness, as measured by pulse wave ve-
locity (PWV).8–14 Longitudinal changes in PWV in relation to 
pulmonary function are unclear, and it remains unknown how 
spirometrically-defined pulmonary function and its change 
affect later PWV. The mechanisms connecting pulmonary 
function and arterial stiffness have not been studied.
To address this gap in research, we assessed the cross-sec-
tional and 5-year prospective associations of forced expiratory 
volume in 1 second (FEV1) with carotid-femoral PWV (cf-
PWV) and its progression. In addition, we examined mecha-
nisms other than the direct effect of pulmonary function on 
arterial stiffness: (1) the possible mediating role of low-grade 
systemic inflammation,8 (2) a possible common-cause expla-
nation considering cardiometabolic factors as the underlying 
causes for both accelerated arterial stiffness and poorer pul-
monary function, and (3) a potential reverse causation (arterial 
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Abstract—Whether poorer pulmonary function accelerates progression of arterial stiffness remains unknown as prior 
observational studies have not examined longitudinal changes in arterial stiffness in relation to earlier pulmonary 
function. Data (N=5342, 26% female) were drawn from the Whitehall II cohort study. Participants completed repeated 
assessments of forced expiratory volume in 1 second (FEV1, L) and carotid-femoral pulse wave velocity (cf-PWV, 
m/s) over 5 years. The effect of FEV1 on later cf-PWV and its progression was estimated using linear mixed-effects 
modeling. Possible explanatory mechanisms, such as mediation by low-grade systemic inflammation, common-cause 
explanation by preexisting cardiometabolic risk factors, and reverse-causation bias, were assessed. Poorer pulmonary 
function was associated with later higher cf-PWV and its subsequent progression (cf-PWV 5-year change 0.09, 95% CI 
0.03–0.17 per SD lower FEV1) after adjustment for age, sex, ethnicity, heart rate, and mean arterial pressure. Decrease 
in pulmonary function was associated with later higher cf-PWV (0.17, 95% CI 0.04–0.30 in the top compared to bottom 
quartile of decline in FEV1). There was no evidence to support mediation by circulating CRP (C-reactive protein) or IL 
(interleukin)-6. Furthermore, arterial stiffness was not associated with later FEV1 after accounting for cardiometabolic 
status. In conclusion, poorer pulmonary function predicted future arterial stiffness. These findings support pulmonary 
function as a clinically important risk factor for arterial stiffness and provide justification for future intervention studies 
for pulmonary function based on its relationship with arterial stiffness.  (Hypertension. 2019;74:929-935. DOI: 10.1161/
HYPERTENSIONAHA.119.13183.)
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stiffness affecting pulmonary function), among middle-aged 
and older men and women.
Methods
Study Population and Design
Data supporting the findings of this study are available from 
the corresponding author on reasonable request (data sharing 
policy: https://www.ucl.ac.uk/epidemiology-health-care/research/
epidemiology-and-public-health/research/whitehall-ii/).
The Whitehall II study started in 1985 and recruited 10308 
London-based civil servants aged 35 to 55 years (6895 men, 3413 
women). Details are published.15 Participants responded to follow-up 
health and lifestyle questionnaire surveys and attended clinical ex-
aminations every 4 to 5 years. Pulmonary function was assessed us-
ing spirometry during clinical examination in 2002/2004, 2007/2009, 
and 2012/2013. Aortic stiffness was measured using cf-PWV during 
the 2007/2009 and 2012/2013 examinations. The analytic sample in-
cluded 5342 participants who had at least 1 measurement of aortic 
stiffness, of whom 3484 provided cf-PWV measurements on both oc-
casions. Research Ethics Committee approval and written informed 
consent from each participant were obtained at each study phase.
Outcome Measure
The cf-PWV measure indexed arterial stiffness. There is an inverse 
relationship between PWV and vascular compliance; therefore, the 
pulse wave travels more quickly through arteries with decreased flex-
ibility than elastic ones. The transit time was defined as the pulse 
wave’s travel time between the carotid and femoral sites in the supine 
position, captured by applanation tonometry (SphygmoCor, Atcor 
Medical, Australia) based on ECG monitoring. Thus, cf-PWV (m/s) 
was calculated by dividing the path length, measured with a tape 
measure using a standard protocol, by the transit time. At each assess-
ment, cf-PWV was measured twice unless the difference between 
measurements was >0.5 m/s when a third measurement was taken. 
The average of the measurements was used in analyses. Extensive 
analysis shows that within-person change in adiposity during the 
study did not have an artifactual effect on measurement of path length 
or on longitudinal change in cf-PWV.16
Main Exposure
Pulmonary function was evaluated through FEV1 (L) using flow-
sensing spirometry (MicroPlus Spirometer, Micro Medical Ltd, Kent, 
United Kingdom) in the standing position. The procedure was con-
ducted by trained nurses following a standard protocol.17 FEV1 was 
measured ≤5×, and the maximum measurement identified. Body size, 
especially standing height, is directly proportional to total lung ca-
pacity. To correct FEV1 for height dependence, we divided by the 
square of the participant’s standing height and multiplied by the 
square of the sample average height: women: 1.61 m, men: 1.75 m.18 
These adjusted values were used in the analyses.
Covariates
Two systemic inflammatory indicators were measured at the 2002 to 
2004 study phase. CRP (C-reactive protein) is an acute phase reac-
tant: a protein produced by the liver in response to induction by IL 
(interleukin)-6. Serum CRP levels were measured through a high-sen-
sitivity immuno-nephelometric assay in a BN ProSpec nephelometer, 
and serum IL-6 level was measured through a high-sensitivity ELISA 
(Dade Behring, Milton Keynes, United Kingdom; R&D Systems, 
Oxford, United Kingdom, respectively).19
Unmodifiable risk factors were the following: sex, age at each 
phase, and ethnicity (white or not). Modifiable risk factors were body 
mass index, waist circumference, systolic blood pressure, mean ar-
terial pressure, heart rate, total cholesterol, high-density lipoprotein 
cholesterol, hemoglobin A1c, smoking status (current smoker or not), 
antihypertensive medication (current user or not), and diabetic sta-
tus (diabetic or not). Each item was examined during the 2007/2009 
phase. Systolic blood pressure, mean arterial pressure, and heart rate 
were also assessed in 2012/2013 because these factors, especially 
mean arterial pressure and heart rate, can affect the cf-PWV meas-
urement by shifting the form of the pulse wave. Follow-up time in 
years between the clinical screening in 2007/2009 and 2012/2013 
was computed and divided by 5 so that a unit change represented a 
time difference of 5 years.
Statistical Analysis
Cuzick nonparametric test was used to test for trend of each vari-
able across quartiles of change in FEV1 between 2002/2004 and 
2007/2009 waves of the study. Linear mixed-effects modeling was 
used to assess the cross-sectional and longitudinal effects of pul-
monary function (2002/2004, 2007/2009, or its change) on arterial 
stiffness (2007/2009, 2012/2013, or its progression), allowing for 
subject-specific random effects for both slope and intercept. To ex-
amine the association between FEV1 and arterial stiffness, the fixed 
part of the model (ignoring covariate terms) for cf-PWV measured 
on individual i on occasion k (=2007/2009 or 2012/2013) at time t:
PWV = Intercept + t + FEV + FEV *tik 1 ik 2 1 i 3 1 i ikβ β β( ) ( )
For measurements at 2007/2009, tik=0, and for measurements at 
2012/2013, tik=time between 2007/2009 and 2012/2013 measure-
ments. In this model, β2 shows the cross-sectional association of 
FEV1 with cf-PWV at 2007/2009, β1 shows how cf-PWV changes 
with time and β3, the coefficient for the interaction term, shows how 
change with time is modified by levels of FEV1. Thus, β3 indicates 
whether FEV1 is associated with progression of cf-PWV over time af-
ter adjusting for the effects of included covariates. In the base model, 
we adjusted for age, sex, ethnicity, heart rate, and mean arterial pres-
sure. Heart rate and mean arterial pressure were also included as 
time-varying covariates.
The effect of changes in FEV1 before baseline cf-PWV 
at 2007/2009 and change in cf-PWV between 2007/2009 and 
2012/2013 were examined by calculating residuals, regressing 
FEV1 at 2007/2009 on FEV1 at 2002/2004. These residuals were 
included in the mixed models for cf-PWV as a continuous varia-
ble and in quartiles. The advantage of using residuals, rather than 
absolute changes in FEV1, is that these residuals are orthogonal to, 
and independent of, baseline FEV1 (2002/2004). Modeling absolute 
changes with baseline adjustment is a questionable method.20 The 
mixed-effect models were estimated using maximum likelihood. 
Likelihood-ratio tests were conducted to test for effect modification 
using fixed-effect interaction terms between pulmonary function 
quartiles and follow-up time.
To explain the relationship between FEV1 and cf-PWV in terms 
of a hypothesized process, we estimated and tested the indirect ef-
fect of FEV1 on cf-PWV and its mediation by inflammation (CRP 
and IL-6) using the Baron and Kenny approach.21 CIs for the per-
centage attenuation were computed using the bootstrap method with 
2000 resamplings.
To investigate reverse causation, linear regression models were 
fitted to estimate the effect of cf-PWV at 2007/2009 on FEV1 at 
2012/2013. Percentage change after adjustment estimated the role of 
cardiometabolic factors as a common cause of arterial stiffness and 
poorer pulmonary function. A sensitivity analysis was conducted to 
examine potential bias arising from chronic respiratory diseases. We 
excluded 623 participants (11.7%) at the 2007/2009 phase with di-
agnosis of chronic obstructive pulmonary disease, asthma, chronic 
bronchitis, pulmonary fibrosis, pneumoconiosis, interstitial pneumo-
nia, pulmonary tuberculosis, or lung cancer.
We imputed missing data using multiple imputation methods 
whose models included all assessments related to participants’ vas-
cular function together with risk factors at the 2007/2009 phase. 
The following auxiliary variables, associated with ≥1 variables 
with missing data, were included in the imputation models: systolic 
blood pressure, mean arterial pressure, heart rate, and forced vital 
capacity from adjacent phases, triglycerides, angina, myocardial in-
farction, stroke, CVD medication, chronic respiratory diseases, and 
alcohol dependence. We generated 20 imputed data sets and com-
bined the results using Rubin rules.22 Statistical significance was 
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defined as a 2-tailed P<0.05. Analyses were conducted using Stata/
MP Ver. 13.1 (StataCorp, TX).
Results
Sample Characteristics
Participants (N=5342) were mean age 65.4 years in 2007/2009. 
The cohort was 26% female and of predominantly white 
ethnic origin. Table 1 shows participant characteristics at 
baseline stratified according to quartiles of change in pulmo-
nary function between 2002/2004 and 2007/2009. Participants 
who showed greater decline of FEV1 were, on average, older, 
male, white ethnicity, and had higher cf-PWV at the start of 
the follow-up. Greater decline in FEV1 was associated with 
being a current smoker, higher waist circumference, higher 
systolic blood pressure, higher mean arterial pressure, and 
lower heart rate. There were no associations with body mass 
index, total cholesterol, or hemoglobin A1c. Medication his-
tory of hypertension and diabetes mellitus were not associated 
with change in FEV1.
Effect of Pulmonary Function on Later Arterial 
Stiffness
Table 2 shows the results of the mixed-effects regression to es-
timate the effect of pulmonary function (FEV1 in 2007/2009, 
FEV1 in 2002/2004, and ΔFEV1 between 2002/2004 and 
2007/2009) on aortic stiffness (cf-PWV in 2007/2009) and 
its subsequent progression (Δcf-PWV between 2007/2009 
and 2012/2013). Lower FEV1 in 2007/2009 was associated 
cross-sectionally with higher cf-PWV in 2007/2009 after ad-
justment for age, sex, ethnicity, mean arterial pressure, and 
heart rate (first panel of Table 2). Cf-PWV was 0.71 m/s (95% 
CI, 0.52–0.91) higher for those in the highest versus lowest 
quartile of FEV1, and a 1 SD lower FEV1 was associated with 
a 0.28 m/s higher cf-PWV. The right-hand side of the first 
panel of Table 2 shows that participants in the highest, com-
pared to the lowest, quartile of FEV1 in 2007/2009 had slower 
subsequent progression of cf-PWV between 2007/2009 and 
2012/2013 after adjusting for other variables. A 1 SD lower 
FEV1 in 2007/2009 was associated with a subsequent faster 
cf-PWV progression.
Similarly, as shown in the second panel of Table 2, lower 
FEV1 measured 5 years earlier in 2002/2004 was associ-
ated with higher cf-PWV in 2007/2009 and faster progres-
sion between 2007/2009 and 2012/2013. Furthermore, in 
the third panel, decrease in FEV1 between 2002/2004 and 
2007/2009 was associated with higher subsequent cf-PWV 
in 2007/2009. Changes in FEV1 between 2002/2004 and 
2007/2009 were not associated with progression of cf-PWV 
between 2007/2009 and 2012/2013 (heterogeneity P=0.65 
across quartiles, trend P=0.84).
As sensitivity analyses, the mixed-effect regressions were 
repeated after excluding participants with prevalent chronic 
Table 1. Characteristics of the Study Participants in 2007/2009 by Quartiles of FEV1 Changes Between 2002/2004 and 2007/2009
Characteristic
Mean (SD) or % by Level of Change in FEV
1
*
P for TrendQ1 (Greatest Decline) Q2 Q3 Q4 (Least Decline)
N (Total 5342) 1336 1336 1335 1335  
FEV
1
 in 2002/2004 3.0 (0.8) 3.2(0.7) 3.4 (0.7) 3.0 (1.0)  
FEV
1
 in 2007/2009 2.3 (0.7) 3.0 (0.6) 3.4 (0.6) 3.6 (0.7)  
Change in FEV
1
−0.6 (0.4) −0.1 (0.1) −0.02 (0.1) 0.7 (0.4)  
Age, y 66.6 (5.7) 65.7 (5.8) 64.8 (5.5) 64.5 (5.6) <0.001
Female sex 18.7% 27.1% 31.9% 28.6% <0.001
White ethnicity 92.9% 93.3% 92.4% 90.2% <0.001
BMI, kg/m2 26.3 (4.0) 26.0 (3.9) 26.2 (4.2) 26.1 (4.0) 0.355
WC, cm 92.3 (11.3) 91.7 (11.2) 89.8 (11.2) 90.2 (11.2) <0.001
cf-PWV, m/s 8.7 (2.3) 8.5 (2.2) 8.3 (2.0) 8.2 (1.9) <0.001
SBP, mm Hg 125.9 (16.1) 124.5 (15.3) 124.3 (15.1) 123.5 (15.4) <0.001
MAP, mm Hg 90.3 (11.1) 89.4 (10.6) 89.4 (10.4) 89.0 (10.5) <0.001
Heart rate, bpm 67.2 (12.2) 67.0 (11.5) 65.8 (11.6) 66.2 (11.2) 0.007
Current smoker, % 8.2% 5.2% 5.3% 5.5% 0.001
TC, mmol/L 5.2 (1.1) 5.3 (1.0) 5.3 (1.1) 5.2 (1.1) 0.441
HDLC, mmol/L 1.6 (0.5) 1.6 (0.4) 1.6 (0.5) 1.6 (0.5) 0.084
HbA1c, % 5.7 (0.6) 5.7 (0.6) 5.7 (0.6) 5.7 (0.6) 0.713
Antihypertensive medication 28.9% 25.8% 26.8% 28.4% 0.512
Diabetic status 3.8% 2.7% 2.8% 3.8% 0.659
Data values shown are % for categorical variables and mean (SD) for continuous variables. BMI indicates body mass index; FEV
1
, forced 
expiratory volume in 1 second; HbA1c, hemoglobin A1c; HDLC, high-density lipoprotein cholesterol; MAP, mean arterial pressure; PWV, 
pulse wave velocity; SBP, systolic blood pressure; TC, total cholesterol; and WC, waist circumference.
*Change in FEV
1
 is calculated as the residuals from a regression of FEV
1
 in 2008/2009 on FEV1 in 2002/2004.
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respiratory diseases. The same associations were observed, 
with lower FEV1 in 2007/2009 or 2002/2004 associated 
with higher cf-PWV in 2007/2009 and faster progression 
of cf-PWV. As previously described, whereas longitudinal 
decreases in FEV1 between 2002/2004 and 2007/2009 were 
significantly associated with higher subsequent cf-PWV in 
2007/2009, FEV1 change (2002/2004 to 2007/2009) was not 
associated with subsequent progression of cf-PWV.
Inflammatory Pathway Mediation Analysis
FEV1 in 2002/2004 was associated cross-sectionally with CRP 
and IL-6 (P<0.001). The mediation effect of inflammatory 
markers on the association between FEV1 in 2002/2004 and 
cf-PWV in 2007/2009 is shown in Table 3. CRP in 2002/2004 
was not associated with cf-PWV in 2007/2009, and the asso-
ciation of FEV1 in 2002/2004 with cf-PWV 2007/2009 was 
not attenuated after CRP adjustment. IL-6 in 2002/2004 was 
weakly associated with cf-PWV in 2007/2009 (P=0.013). 
IL-6 adjustment did not attenuate the association between 
FEV1 and cf-PWV. Similarly, adjustment for smoking status 
had negligible effect on this association (attenuation 0.01%; 
95% CI, −5.1 to 5.2).
Reverse Causation
The association between cf-PWV in 2007/2009 and FEV1 in 
2012/13 was examined before and after adjustment for cardio-
metabolic status (Table 4). In the base model, higher cf-PWV 
in 2007/2009 was weakly associated with poorer FEV1 in 
2012/2013. Cardiometabolic factors (systolic blood pressure, 
body mass index, waist circumference, total cholesterol, he-
moglobin A1c, and smoking status) were added to the model. 
The association between cf-PWV and later FEV1 was not at-
tenuated significantly, although the PWV-FEV1 association 
was not significant (P=0.053) in the adjusted model.
Discussion
This large longitudinal study provides new evidence for poor 
pulmonary function as a risk factor for aortic stiffness in 
early old age. The present findings show that (1) lower FEV1 
was associated with later higher cf-PWV and its subsequent 
Table 2. Association Between FEV1 (L) cf-PWV (m/s) During the Follow-Up Period
Pulmonary Function cf-PWV at Baseline (2007/2009) Change in cf-PWV (per 5 y)
FEV Measure Median
Person 
Observations (n) Mean
Difference 
(95% CI) P Value Mean
Difference 
(95% CI) P value
FEV
1
 in 2007/2009  (8819)       
  Q1-lowest quartile 1.87 2137 8.83 Ref. … 0.71 Ref. …
  Q2 2.82 2202 8.54 −0.28 (−0.44 to −0.12) 0.001 0.62 −0.09 (−0.32 to 0.15) 0.46
  Q3 3.53 2231 8.31 −0.53 (−0.71 to −0.34) < 0.001 0.70 −0.01 (−0.24 to 0.21) 0.93
  Q4-highest quartile 4.16 2249 8.12 −0.71 (−0.91 to −0.52) < 0.001 0.38 −0.32 (−0.55 to −0.09) 0.007
LR test* (P value)    …   0.023  
Per 1 SD higher FEV
1
   −0.28 (−0.36 to −0.22) < 0.001  −0.09 (−0.17 to −0.03) 0.011
FEV
1
 in 2002/2004  (8819)       
  Q1-lowest quartile 2.04 2152 8.78 Ref. … 0.71 Ref. …
  Q2 2.99 2183 8.55 −0.24 (−0.40 to −0.08) 0.003 0.60 −0.10 (−0.33 to 0.13) 0.40
  Q3 3.69 2242 8.33 −0.46 (−0.65 to −0.28) < 0.001 0.69 −0.01 (−0.24 to 0.22) 0.92
  Q4-highest quartile 4.20 2242 8.14 −0.64 (−0.84 to −0.45) < 0.001 0.38 −0.32 (−0.55 to −0.09) 0.006
LR test (P value)    …   0.019  
Per 1 SD higher FEV
1
   −0.25 (−0.32 to −0.18) < 0.001  −0.10 (−0.18 to −0.02) 0.012
FEV
1
 change quartile  (8819)       
  Q1-greatest decline −0.53 2183 8.53 Ref. … 0.68 Ref. …
  Q2 −0.20 2191 8.49 −0.04 (−0.17 to 0.09) 0.53 0.53 −0.16 (−0.26 to 0.14) 0.89
  Q3 −0.01 2211 8.45 −0.07 (−0.20 to 0.07) 0.32 0.55 −0.12 (−0.36 to 0.11) 0.31
  Q4-least decline 0.57 2234 8.36 −0.17 (−0.30 to −0.04) 0.011 0.58 −0.11 (−0.35 to 0.13) 0.38
LR test (P value)    …   0.65  
Per 1 SD higher FEV
1
 
change
   −0.08 (−0.16 to −0.01) 0.032  −0.02 (−0.25 to 0.20) 0.84
Models adjusted for age, sex, ethnicity, heart rate, and mean arterial pressure. Means are shown adjusted to white men at age 65 with mean arterial pressure of 90 
mm Hg and heart rate of 70 bpm. The effect of lung function on cf-PWV at baseline (2007/2009) is estimated by the coefficient for the main effect of FEV1. The effect on 
change in cf-PWV between 2007/2009 and 2012/2013 is estimated by the interaction of the main effect with follow-up time. Cut points used for FEV
1
 in 2002/2004 are 
those used for FEV
1
 in 2007/2009. cf-PWV indicates carotid-femoral PWV; FEV
1
, Forced expiratory volume in 1 second; LR, likelihood ratio; and PWV, pulse wave velocity.
*P value from likelihood ratio test for heterogeneity of changes in cf-PWV across quartiles.
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longitudinal progression after adjustment for age, sex, eth-
nicity, heart rate, and mean arterial pressure; (2) 5-year de-
crease in FEV1 was associated with higher cf-PWV, whereas 
the FEV1 decrease was not associated with progression of 
aortic stiffness; (3) there was little evidence that the associa-
tion between poorer pulmonary function and later higher aortic 
stiffness was mediated by circulating inflammatory markers 
CRP and IL-6; and (4) higher cf-PWV was only weakly as-
sociated with later impairment of FEV1 after adjustment for 
cardiometabolic status, suggesting that there was no strong 
evidence for reverse causation. The current evidence supports 
the clinical importance of observing pulmonary function as a 
new marker or potential cause for aortic stiffness.
We hypothesized that the association between poorer 
pulmonary function and higher arterial stiffness would be 
mediated by low-grade systemic inflammation. The human 
respiratory system is thought to be particularly vulnerable 
to environmental factors because it has a large interface with 
the outside world. Exposure to environmental factors can 
cause poorer pulmonary function with acute or chronic res-
piratory inflammation. This could result in low-grade sys-
temic inflammation, which can be measured through higher 
blood concentration of CRP and IL-6.23 Systemic inflamma-
tion might contribute to, or trigger, the process of remod-
eling within vascular walls of arteries, resulting in elastic 
fibers’ degradation and their replacement by collagen dep-
osition.24–26 Studies focusing on low-grade systemic inflam-
mation have typically assessed only CRP. Despite CRP being 
a general marker of inflammatory processes, IL-6 may be a 
more sensitive and appropriate marker of systemic inflam-
mation through regulation of CRP synthesis and assumed 
causal association with cardiovascular end points, such as 
myocardial infarction.27 However, research on the relation-
ship between IL-6 and lung function is also scarce.28–30 Our 
mediation analysis showed that the association between 
poorer pulmonary function and higher arterial stiffness was 
unchanged when CRP was used as marker of inflammation 
and insignificantly mediated by only 5.1% (95% CI, −1.2 to 
11.5) when IL-6 was used. Therefore, we found little evi-
dence that the effect of FEV1 on cf-PWV could be attributed 
to mediation by low-grade systemic inflammation, despite 
the plausibility of this pathophysiological mechanism. This 
finding was supported by sensitivity analysis, excluding 
people with chronic respiratory disease.
Analyses to investigate reverse causation were included 
in this study. Higher cf-PWV was a predictor of later lower 
FEV1, but the association was weak. After controlling for car-
diometabolic factors, the cf-PWV- FEV1 association was not 
significant. Two inferences can be made. First, cardiometa-
bolic status does not seem to play an important role as a com-
mon cause of higher arterial stiffness and poorer pulmonary 
function. Second, the prospective association may be due en-
tirely to confounding by cardiometabolic status. In summary, 
the evidence that aortic stiffness is a determinant of pulmo-
nary function in our cohort is weak.
The balance of our findings suggests pulmonary function 
may have direct impact on arterial stiffness. Poor pulmonary 
function may lead to an imbalance between demand and sup-
ply of oxygen in the arterial wall to cause aortic stiffening. 
Development of atherosclerotic lesions may contribute con-
currently to arterial stiffening.31,32 Alternatively, the associa-
tion between pulmonary function and aortic stiffness could 
partly be due to shared structural and mechanical properties 
of the 2 organs. Elastin may be important in this context, as a 
protein conferring distensibility and elastic recoil to connec-
tive tissue in the aortic wall and lung. Serine proteases and 
matrix metalloproteinases are able to degrade elastin, contrib-
uting to loss of elasticity and potentially to correlated proper-
ties of aorta and lung.8,11,33
We did not find evidence to support an effect of longitu-
dinal changes in pulmonary function on later cf-PWV change, 
possibly because the study lacked statistical power. If direct 
impact of pulmonary function on arterial stiffness is assumed, 
then, in theory, there should be a significant association be-
tween change in FEV1 and later change in cf-PWV. However, 
the mean change in cf-PWV over about 5 years (between 
2007/2009 and 2012/2013) was <0.7 m/s; hence, the study 
may be underpowered to detect such a small effect.
Table 3. Mediation of the Association Between FEV1 in 2002/2004 and cf-PWV 
in 2007/2009 by Circulating Inflammatory Factors
Model Coefficient* (95% CI)
Attenuation
Percent 95% CI†
Base‡ −0.227 (−0.323 to −0.131) … …
Base+CRP −0.226 (−0.323 to −0.129) 0.5% (−4.6 to 5.6)
Base+IL-6 −0.215 (−0.314 to −0.117) 5.1% (−1.2 to 11.5)
Base+CRP, IL-6 −0.215 (−0.314 to −0.117) 5.1% (−2.0 to 12.2)
cf-PWV indicates carotid-femoral PWV; CRP, C-reactive protein; FEV
1
, Forced 
expiratory volume in 1 second; and IL, interleukin.
*Coefficient shows effect of a 1 SD increase in FEV in 2002/2004 on PWV in 
2007/2009.
†Bootstrap CI.
‡Base model adjusted for age, sex, mean arterial pressure, and heart rate.
Table 4. Reverse Causation—Associations of cf-PWV in 2007/2009 With FEV1 in 2012/2013
Model Coefficient* (95% CI) P Value
Attenuation
Percent 95% CI†
Base‡ −0.013 (−0.025 to −0.0004) 0.042 … …
Base+cardiometabolic status§ −0.012 (−0.025 to 0.0001) 0.053 3.5% (−33.9 to 40.9)
BP indicates blood pressure; cf-PWV indicates carotid-femoral PWV; CRP, C-reactive protein; and FEV
1
, forced expiratory volume in 1 second.
*Coefficient shows effect of a 1 SD increase in cf-PWV in 2007/2009 on FEV
1
 in 2012/2013.
†95% CI from bootstrap method.
‡Base model adjusted for age, sex, ethnicity, mean arterial pressure, and time interval between 2007/2009 and 2012/2013 assessments.
§Cardiometabolic status includes systolic BP, body mass index, waist circumference, total cholesterol, hemoglobin A1c, and smoking status.
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The main strength of this study lies in its longitudinal de-
sign, including repeated measurements of pulmonary function 
and arterial stiffness over time, which enabled us to address 
causality. To our knowledge, this is the first study to assess 
the impact of longitudinal changes in FEV1 on later aortic 
stiffness and its progression in early old age. Three statistical 
approaches were applied to examine the direct effect, possible 
pathway, and reverse causation. Another strength is the large 
study sample which included both men and women. This is 
one of the largest observational studies examining the associa-
tion between pulmonary function and arterial stiffness, which 
enables us not only to have good statistical power but also to 
validate the reference value of FEV1 and to avoid spurious dif-
ferences because of sampling error.
Regarding this study’s limitations, unmeasured confound-
ing factors might also affect the association between pul-
monary function and arterial stiffness. For example, genetic 
factors or susceptibility might contribute to spurious associa-
tions.6,34,35 Simultaneous loss of flexibility in the connective 
tissue of both alveoli and arterial walls due to genetic fac-
tors could plausibly lead to both impaired pulmonary func-
tion and higher arterial stiffness because elastin is known to 
confer elasticity to both organs. In the context of common 
origins, the direct effect of FEV1 on cf-PWV captured in the 
current study cannot be separated from the effects of genetic 
factors or shared pathological mechanisms. Furthermore, the 
Developmental Origins of Health And Disease hypothesis 
demonstrates that adverse exposures in early life could lead 
to permanent structural and metabolic changes, resulting in 
both pulmonary and CVDs in later life.36,37 If impaired pul-
monary function and higher arterial stiffness share early life 
origins, it will be also necessary to keep in mind that early 
life prevention could be indicated, although the evidence cur-
rently available for the shared origins is limited. In addition, 
within-person longitudinal variability of inflammatory mark-
ers may bias attenuation towards the null in the mediation 
analysis,38 although recent analyses, based on the same cohort 
study, examining IL-6 and CRP have suggested such varia-
bility could be a relatively minor concern.39,40
Finally, the data used in this study were from middle- to 
older-aged, white-collar, London-based civil servants; there-
fore, the generalisability of this study’s findings need to be 
confirmed in future research including other generations, eth-
nicities, and occupation types. In the context of standard risk 
factor-CVD associations, despite marked differences in both 
risk factors and disease incidence, close agreement between 
the findings from Whitehall II and general population samples 
have been found.41
Perspective
The present findings suggest that pulmonary function could 
have predictive value for future increases in arterial stiffness 
and its progression. To clarify the causal effect of pulmonary 
function measured by FEV1 on later aortic stiffness, a pos-
sible indirect pathway through mediation by inflammation 
and reverse causation considering cardiometabolic status were 
investigated. These results imply that the association between 
poorer pulmonary function and later increase in aortic stiff-
ness is not mediated by systemic inflammation indicated by 
elevated levels of CRP and IL-6. Furthermore, higher cf-PWV 
does not predict later impairment of FEV1 after accounting for 
cardiometabolic status.
Future intervention studies are needed to clarify the pre-
ventive effect of monitoring and intervening in lung function 
on aortic stiffness progression. The current evidence supports 
the clinical importance of observing pulmonary function as 
a new potential cause for aortic stiffness. Considering the 
feasible nature of spirometry as a routine clinical examina-
tion, FEV1 may be an effective potential option for improving 
health management and facilitating CVD prevention.
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What Is New?
•	This article provides evidence on the predictive importance of poor lung 
function in relation to future increases in arterial stiffness and its pro-
gression among men and women, accounting for possible explanatory 
mechanisms.
What Is Relevant?
•	The current findings support the clinical value of observing lung function 
as a new marker or potential cause for vascular aging, which is relevant 
to hypertension and its related diseases.
Summary
Poor lung function predicted future arterial stiffness. This supports 
lung function as a clinically important risk factor for arterial stiff-
ness and provides justification for future intervention studies for 
lung function based on its relationship with arterial stiffness.
Novelty and Significance
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